Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Sep;33(9):1962-3.
doi: 10.2337/dc10-0814.

No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial

Carla Bizzarri  1 , Dario Pitocco, Nicola Napoli, Enrico Di Stasio, Daria Maggi, Silvia Manfrini, Concetta Suraci, Maria Gisella Cavallo, Marco Cappa, Giovanni Ghirlanda, Paolo Pozzilli; IMDIAB Group
Collaborators, Affiliations
Randomized Controlled Trial

No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial

Carla Bizzarri et al. Diabetes Care. 2010 Sep.

Abstract

Objective: We investigated whether supplementation of the active form of vitamin D (calcitriol) in recent-onset type 1 diabetes can protect beta-cell function evaluated by C-peptide and improve glycemic control assessed by A1C and insulin requirement.

Research design and methods: Thirty-four subjects (aged 11-35 years, median 18 years) with recent-onset type 1 diabetes and high basal C-peptide >0.25 nmol/l were randomized in a double-blind trial to 0.25 microg/day calcitriol or placebo and followed-up for 2 years.

Results: At 6, 12, and 24 months follow-up, A1C and insulin requirement in the calcitriol group did not differ from the placebo group. C-peptide dropped significantly (P < 0.001) but similarly in both groups, with no significant differences at each time point.

Conclusions: At the doses used, calcitriol is ineffective in protecting beta-cell function in subjects (including children) with recent-onset type 1 diabetes and high C-peptide at diagnosis.

Trial registration: ClinicalTrials.gov NCT01120119.

PubMed Disclaimer

References

    1. Mathieu C, Gysemans C, Giulietti A, Bouillon R: Vitamin D and diabetes. Diabetologia 2005;48:1247–1257 - PubMed
    1. The EURODIAB Substudy 2 Study Group. Vitamin D supplements in early childhood and risk for type I (insulin dependent) diabetes mellitus. Diabetologia 1999;42:51–54 - PubMed
    1. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500–1503 - PubMed
    1. Pitocco D, Crinò A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, Anguissola GB, Visalli N, Suraci C, Matteoli MC, Patera IP, Cavallo MG, Bizzarri C, Pozzilli P: the IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset type 1 diabetes (IMDIAB XI). Diabet Med 2006;23:920–923 - PubMed
    1. Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG: No Effect of the 1α,25-dihydroxyvitamin D3 on β-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010;33:1443–1448 - PMC - PubMed

Publication types

Associated data